Teratogenicity
Intrauterine Drug Delivery Systems
Drug Regulation
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Transdermal Drug Delivery Systems
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jun 12, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Meng Chen1, Sean D Doherty, Sylvia Hsu
1Department of Dermatology, Baylor College of Medicine, BCM Debakey Building M220, One Baylor Plaza, Mail Stop BCM368, Houston, TX 77030, USA.
Thalidomide, approved for specific conditions, shows promise in treating various refractory dermatologic disorders off-label. This review explores its background, pharmacology, and innovative dermatological applications.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: